Department of Pharmacology and Pharmacy, The University of Hong Kong

Mr. Franco W.T. CHENG 鄭永德



  • BPharm, MClinPharm

Mr Franco Cheng obtained both his Bachelor of Pharmacy and Master of Clinical Pharmacy at the Chinese University of Hong Kong. Prior to joining HKU as a pharmacist in 2021, Franco worked in both private and public hospitals in Hong Kong with extensive exposure to cardiology, nephrology, infectious diseases, critical care, respiratory diseases and bariatric surgery. He then joined HKU as a research pharmacist in COVID-19 Vaccines Adverse Events Response and Evaluation (CARE) Programme prior to taking up the lecturer position.

Memberships & Editorships


  • Registered Pharmacist (Hong Kong)
  • Treasurer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) HK Chapter
  • Governor, International Society of Cardiovascular Pharmacotherapy (ISCP)
  • Board Certified Pharmacotherapy Specialist, Board of Pharmacy Specialties (USA)
  • Board Certified Cardiology Pharmacist, Board of Pharmacy Specialties (USA)
  • Board Member, Asian Conference on Clinical Pharmacy


  • Editorial Board, European Cardiology Review
  • Editor, Research in Clinical Pharmacy

Research Interests
  • Big data research: epidemiology and pharmacoepidemiology
  • Nephrology
  • Cardiology
  • Pharmacy Practice

Selected Publications
  • Cheng FWT, Fan M, Wong CKH, et al. The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases. Kidney Int. 2022;102(4):922-925. doi:10.1016/j.kint.2022.07.018 [2021 IF: 18.998]
  • Cheng FWT, Wong CKH, Qin SX, et al. Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines [published online ahead of print, 2022 Oct 28]. Nephrol Dial Transplant. 2022;gfac292. doi:10.1093/ndt/gfac292 [2021 IF: 7.186]
  • Wong CKH, Mak LY, Au ICH,…,Cheng FWT…Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77(5):1339-1348. doi:10.1016/j.jhep.2022.06.032 [2021 IF: 30.083]
  • Wong CKH, Lau KTK, Xiong X,…,Cheng FWT… Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS Med. 2022;19(6):e1004018. Published 2022 Jun 21. doi:10.1371/journal.pmed.1004018 [2021 IF: 11.613]
  • Cheng FWT, So SWK, Fung BWT, Hung WH, Lee VWY. Online drug information platform for the public in Hong Kong-Review of local drug information use and needs. Int J Med Inform. 2018;114:27-34. doi:10.1016/j.ijmedinf.2018.03.006 [2021 IF: 5.537]
  • Lee VWY, Fong FYH, Cheng FWT, Yan BPY. Life's simple 7 and cardiovascular disease risk knowledge in Hong Kong. BMC Cardiovasc Disord. 2019;19(1):185. Published 2019 Aug 2. doi:10.1186/s12872-019-1171-7 [2021 IF: 2.298]
  • Lee VWY, Yan BP, Fong TMC, Fung AKP, Cheng FWT. Long-term health-related burden of adult congenital heart diseases in Hong Kong. J Med Econ. 2019;22(8):814-817. doi:10.1080/13696998.2019.1613239 [2021 IF: 2.448]
  • Lee VW, Choi LM, Wong WJ, Chung HW, Ng CK, Cheng FW. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. BMC Cardiovasc Disord. 2015;15:178. Published 2015 Dec 24. doi:10.1186/s12872-015-0173-3 [2021 IF: 2.298]